SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
TG Therapeutics, Inc. Initiates First-In-Human, Phase I Clinical Trial for Its Novel, Highly Specific PI3K-Delta Inhibitor, TGR-1202, in Patients With Hematologic Malignancies